Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Cereno Scientific

8,26 SEK

0,00 %

Mindre end 1K følgere

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
0,00 %
+12,76 %
-12,59 %
-23,09 %
+50,18 %
+39,17 %
+276,31 %
+324,46 %
+37,41 %

Cereno Scientific is active in biotechnology. The company specializes in drug development for common and rare cardiovascular diseases. The main drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension (PAH), as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. The head office is in Mölndal with offices also in North America.

Læs mere
Markedsværdi
2,56 mia. SEK
Aktieomsætning
3,95 mio. SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
27.2
2026

Årsrapport '25

Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Pressemeddelelse3.12.2025, 07.00

Cereno Scientific to Present New Data of CS014 at the Pharmacology 2025 on December 15-18

Cereno Scientific
Selskabsmeddelelse30.11.2025, 09.17

Correction: Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027

Cereno Scientific
Pressemeddelelse28.11.2025, 18.31

Cereno Scientific: Major shareholders and new investors back the Company's long-term strategy with equity investment at a premium

Cereno Scientific

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse28.11.2025, 18.30

Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027

Cereno Scientific
Selskabsmeddelelse27.11.2025, 06.30

Cereno Scientific Publishes Interim Report for Q3 2025 (July 1 - September 30, 2025)

Cereno Scientific
Selskabsmeddelelse11.11.2025, 06.45

Cereno Scientific Receives SEK 4 million Through Exercise of 600,000 Warrants by Arena Investors, LP

Cereno Scientific
Pressemeddelelse10.11.2025, 12.40

BioStock: Cereno Scientific takes the next step towards phase IIb study in PAH

Cereno Scientific
Pressemeddelelse10.11.2025, 06.45

Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. FDA

Cereno Scientific
Pressemeddelelse15.10.2025, 05.45

Cereno Scientific to Participate at BIO-Europe Fall 2025 in Vienna - the Global BioPharma Partnering Event

Cereno Scientific
Pressemeddelelse24.9.2025, 06.00

Cereno Scientific Participates at Partnering and Investor Conference Nordic Life Science Days 2025

Cereno Scientific
Selskabsmeddelelse15.9.2025, 09.15

Cereno Scientific Announces Conversion of All Remaining Convertibles Following Request by Fenja Capital II A/S and Arena Investors, LP

Cereno Scientific
Pressemeddelelse3.9.2025, 06.00

Cereno Scientific Announces Sten R. Sörensen Named Finalist for `CEO of the Year' at the European Lifestars Awards 2025

Cereno Scientific
Pressemeddelelse2.9.2025, 06.00

Cereno Scientific Participates at GoCo Investor Day on September 9, 2025, in Gothenburg

Cereno Scientific
Eksterne analyser29.8.2025, 06.55

Cereno Scientific: Momentum building ahead of Phase II - Edison

Cereno Scientific’s Q225 results demonstrated steady progress across its clinical assets, with encouraging developments post-period. CS1 continues to edge closer to a Phase IIb trial in pulmonary arterial hypertension (PAH), with the recent Fast Track...

Cereno Scientific
Selskabsmeddelelse27.8.2025, 06.00

Cereno Scientific Publishes Interim Report for Q2 2025 (April 1 - June 30, 2025)

Cereno Scientific
Selskabsmeddelelse26.8.2025, 09.40

Cereno Scientific Granted FDA Fast Track Designation for CS1 in Rare Disease Pulmonary Arterial Hypertension (PAH)

Cereno Scientific
Selskabsmeddelelse6.8.2025, 16.00

Cereno Scientific announces conversion of convertibles following request by Fenja Capital II A/S and Arena Investors, LP

Cereno Scientific
Eksterne analyser17.7.2025, 07.52

Cereno Scientific: Phase II calling for CS014 after Phase I success - Edison

Cereno Scientific reported positive Phase I readouts for CS014, its novel HDAC inhibitor, paving the way for Phase II studies in idiopathic pulmonary fibrosis (IPF). The candidate demonstrated favourable safety and tolerability in healthy volunteers ...

Cereno Scientific
Selskabsmeddelelse15.7.2025, 11.05

Cereno Scientific announces positive topline results from Phase I trial of CS014 - a novel HDAC inhibitor - supporting advancement into Phase II

Cereno Scientific
Pressemeddelelse4.7.2025, 06.00

Cereno Scientific selects top-tier global CRO for Phase IIb trial of CS1 in the rare disease pulmonary arterial hypertension

Cereno Scientific
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.